MedTrace Logo

Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma

NCT01175902 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2015-01-08

Study results available
· View outcomes & findings →

Summary

To prove the non-inferiority of the fixed timolol-dorzolamide combination (Cosopt) compared to 0.005% latanoprost (Xalatan) in the aspects of intraocular pressure (IOP) and ocular perfusion pressure (OPP) in subjects with normal tension glaucoma (NTG)

Clinical hypotheses. Primary hypothesis

* Cosopt group is non-inferior to Xalatan group in diurnal IOP reduction.

Secondary hypothesis

* Cosopt group is non-inferior to Xalatan group in diurnal diastolic and systolic OPP.

Conditions

  • Normal Tension Glaucoma

Interventions

DRUG

dorzolamide/timolol

dorzolamide/timolol fixed combination eyedrop, 2 times a day

DRUG

latanoprost

compare with dorzolamide/timolol fixed combination eyedrop one time a day

Sponsors & Collaborators

  • Seoul St. Mary's Hospital

    collaborator OTHER

  • The Catholic University of Korea

    lead OTHER

Principal Investigators

  • Chan Kee Park, M.D., PhD. · The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01175902 on ClinicalTrials.gov